{"pmid":32400371,"title":"[Anosmia and ageusia as primary symptoms of COVID-19].","text":["[Anosmia and ageusia as primary symptoms of COVID-19].","This case report describes a physician in the early 30ies with subjective anosmia and ageusia as the major presenting symptoms of COVID-19. Apart from a week of slightly runny nose when coming from cold to warm air, the only symptom was a sudden onset of persistent anosmia and ageusia. Two weeks after normalisation of the mild sino-nasal symptoms, the patient was tested positive for SARS-CoV-2, and anosmia was verified with Sniffin' Sticks tests. Hypogeusia was verified with taste screening and two validated taste tests. Olfactory and gustatory loss may be underestimated symptoms of COVID-19.","Ugeskr Laeger","Haldrup, Mette","Johansen, Mikkel Illemann","Fjaeldstad, Alexander Wieck","32400371"],"abstract":["This case report describes a physician in the early 30ies with subjective anosmia and ageusia as the major presenting symptoms of COVID-19. Apart from a week of slightly runny nose when coming from cold to warm air, the only symptom was a sudden onset of persistent anosmia and ageusia. Two weeks after normalisation of the mild sino-nasal symptoms, the patient was tested positive for SARS-CoV-2, and anosmia was verified with Sniffin' Sticks tests. Hypogeusia was verified with taste screening and two validated taste tests. Olfactory and gustatory loss may be underestimated symptoms of COVID-19."],"journal":"Ugeskr Laeger","authors":["Haldrup, Mette","Johansen, Mikkel Illemann","Fjaeldstad, Alexander Wieck"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400371","source":"PubMed","week":"202020|May 11 - May 17","locations":["sino-nasal"],"topics":["Diagnosis"],"weight":1,"_version_":1666714494764580866,"score":9.490897,"similar":[{"pmid":32342566,"title":"Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases.","text":["Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases.","BACKGROUND: The first European case series are detecting a very high frequency of chemosensitive disorders in COVID-19 patients, ranging between 19.4% and 88%. METHODS: Olfactory and gustatory function was objectively tested in 72 COVID-19 patients treated at University Hospital of Sassari. RESULTS: Overall, 73.6% of the patients reported having or having had chemosensitive disorders. Olfactory assessment showed variable degree hyposmia in 60 cases and anosmia in two patients. Gustatory assessment revealed hypogeusia in 33 cases and complete ageusia in one patient. Statistically significant differences in chemosensitive recovery were detected based on age and distance from the onset of clinical manifestations. CONCLUSION: Olfactory and gustatory dysfunctions represent common clinical findings in COVID-19 patients. Otolaryngologists and head-neck surgeons must by now keep this diagnostic option in mind when evaluating cases of ageusia and nonspecific anosmia that arose suddenly and are not associated with rhinitis symptoms.","Head Neck","Vaira, Luigi Angelo","Deiana, Giovanna","Fois, Alessandro Giuseppe","Pirina, Pietro","Madeddu, Giordano","De Vito, Andrea","Babudieri, Sergio","Petrocelli, Marzia","Serra, Antonello","Bussu, Francesco","Ligas, Enrica","Salzano, Giovanni","De Riu, Giacomo","32342566"],"abstract":["BACKGROUND: The first European case series are detecting a very high frequency of chemosensitive disorders in COVID-19 patients, ranging between 19.4% and 88%. METHODS: Olfactory and gustatory function was objectively tested in 72 COVID-19 patients treated at University Hospital of Sassari. RESULTS: Overall, 73.6% of the patients reported having or having had chemosensitive disorders. Olfactory assessment showed variable degree hyposmia in 60 cases and anosmia in two patients. Gustatory assessment revealed hypogeusia in 33 cases and complete ageusia in one patient. Statistically significant differences in chemosensitive recovery were detected based on age and distance from the onset of clinical manifestations. CONCLUSION: Olfactory and gustatory dysfunctions represent common clinical findings in COVID-19 patients. Otolaryngologists and head-neck surgeons must by now keep this diagnostic option in mind when evaluating cases of ageusia and nonspecific anosmia that arose suddenly and are not associated with rhinitis symptoms."],"journal":"Head Neck","authors":["Vaira, Luigi Angelo","Deiana, Giovanna","Fois, Alessandro Giuseppe","Pirina, Pietro","Madeddu, Giordano","De Vito, Andrea","Babudieri, Sergio","Petrocelli, Marzia","Serra, Antonello","Bussu, Francesco","Ligas, Enrica","Salzano, Giovanni","De Riu, Giacomo"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32342566","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/hed.26204","keywords":["covid-19","ageusia","anosmia","gustatory function","olfactory function"],"locations":["Otolaryngologists"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495109824512,"score":290.44794},{"pmid":32422426,"title":"Importance of SARs-Cov-2 anosmia: From phenomenology to neurobiology.","text":["Importance of SARs-Cov-2 anosmia: From phenomenology to neurobiology.","Anosmia and hypogeusia, the inability or decreased ability to smell and taste, have been reported as common complaints in SARS-CoV-2 patients who were still in an asymptomatic phase. These impairments affect the ability to sense odors in foods and the environment, obviously affecting quality of life, related to social interactions and general well-being. The British Association of Otorhinolaryngology (ENT-UK) considers loss of sense of smell in their list of COVID-19's markers of infection. Here we present two cases in which early manifestations of anosmia and hypogeusia were experienced with psycho-sensorial and atmospheric phenomena. Psychiatrists, neurologists and physicians in general should be aware of this symptom presentation in order to avoid mistreatment, given that persistent olfactory dysfunction might increase the risks of nutritional deficit and lead to development of adjustment disorders. All clinicians should be aware that the presentation of SARS-CoV-2's symptoms goes far beyond respiratory and sensorial dimensions and involves psychosensorial and neurological dimensions; these clinical observations could shed light on the neurobiological substrates involved in COVID-19 disease.","Compr Psychiatry","Pallanti, Stefano","32422426"],"abstract":["Anosmia and hypogeusia, the inability or decreased ability to smell and taste, have been reported as common complaints in SARS-CoV-2 patients who were still in an asymptomatic phase. These impairments affect the ability to sense odors in foods and the environment, obviously affecting quality of life, related to social interactions and general well-being. The British Association of Otorhinolaryngology (ENT-UK) considers loss of sense of smell in their list of COVID-19's markers of infection. Here we present two cases in which early manifestations of anosmia and hypogeusia were experienced with psycho-sensorial and atmospheric phenomena. Psychiatrists, neurologists and physicians in general should be aware of this symptom presentation in order to avoid mistreatment, given that persistent olfactory dysfunction might increase the risks of nutritional deficit and lead to development of adjustment disorders. All clinicians should be aware that the presentation of SARS-CoV-2's symptoms goes far beyond respiratory and sensorial dimensions and involves psychosensorial and neurological dimensions; these clinical observations could shed light on the neurobiological substrates involved in COVID-19 disease."],"journal":"Compr Psychiatry","authors":["Pallanti, Stefano"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422426","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.comppsych.2020.152184","keywords":["anosmia","covid-19","early symptoms","hypogeusia","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1667254896802398208,"score":278.4703},{"pmid":32383370,"title":"Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients.","text":["Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients.","Initially, acute loss of smell (anosmia) and taste (ageusia) was not considered important symptoms for coronavirus disease 2019 (COVID-19). To determine the prevalence of these symptoms and to evaluate their diagnostic significance, we (approximately 150 physicians of the Daegu Medical Association) prospectively collected data of cases of anosmia and ageusia from March 8, 2020, via telephone interview among 3,191 patients in Daegu, Korea. Acute anosmia or ageusia was observed in 15.3% (488/3,191) patients in the early stage of COVID-19 and in 15.7% (367/2,342) patients with asymptomatic-to-mild disease severity. Their prevalence was significantly more common among females and younger individuals (P = 0.01 and P < 0.001, respectively). Most patients with anosmia or ageusia recovered within 3 weeks. The median time to recovery was 7 days for both symptoms. Anosmia and ageusia seem to be part of important symptoms and clues for the diagnosis of COVID-19, particularly in the early stage of the disease.","J Korean Med Sci","Lee, Yonghyun","Min, Pokkee","Lee, Seonggu","Kim, Shin Woo","32383370"],"abstract":["Initially, acute loss of smell (anosmia) and taste (ageusia) was not considered important symptoms for coronavirus disease 2019 (COVID-19). To determine the prevalence of these symptoms and to evaluate their diagnostic significance, we (approximately 150 physicians of the Daegu Medical Association) prospectively collected data of cases of anosmia and ageusia from March 8, 2020, via telephone interview among 3,191 patients in Daegu, Korea. Acute anosmia or ageusia was observed in 15.3% (488/3,191) patients in the early stage of COVID-19 and in 15.7% (367/2,342) patients with asymptomatic-to-mild disease severity. Their prevalence was significantly more common among females and younger individuals (P = 0.01 and P < 0.001, respectively). Most patients with anosmia or ageusia recovered within 3 weeks. The median time to recovery was 7 days for both symptoms. Anosmia and ageusia seem to be part of important symptoms and clues for the diagnosis of COVID-19, particularly in the early stage of the disease."],"journal":"J Korean Med Sci","authors":["Lee, Yonghyun","Min, Pokkee","Lee, Seonggu","Kim, Shin Woo"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383370","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.3346/jkms.2020.35.e174","keywords":["ageusia","anosmia","covid-19","loss of smell","loss of taste"],"locations":["Daegu","South Korea"],"countries":["Korea, Republic of"],"countries_codes":["KOR|Korea, Republic of"],"topics":["Diagnosis"],"weight":1,"_version_":1666267276786008064,"score":274.9368},{"pmid":32447496,"title":"The role of self-reported smell and taste disorders in suspected COVID19.","text":["The role of self-reported smell and taste disorders in suspected COVID19.","PURPOSE: The sudden onset of smell and taste loss has been reported as a symptom related to COVID-19. There is urgent need to provide insight to the pandemic and evaluate anosmia as a potential screening symptom that might contribute to the decision to test suspected cases or guide quarantine instructions. METHODS: Systematic review of the PubMed/Medline, Cochrane databases and preprints up to May 3, 2020. Combined search terms included: \"COVID-19\", \"SARS-CoV-2\", \"coronavirus\", \"nose\", \"anosmia\", \"hyposmia\", \"olfactory loss\", \"smell loss\", \"taste loss\", and \"hypogeusia\". RESULTS: Our search identified 18 reviewed articles and 6 manuscript preprints, including a large epidemiological study, four observational case series, five case-controlled studies, five cross-sectional studies, five case series of anosmic patients and four electronic surveys. Great methodological differences were noted. A significant prevalence of anosmia is reported in COVID-19 patients. Controlled studies indicate that anosmia is more common in COVID-19 patients than in patients suffering from other viral infections or controls. Most of the studies reported either smell loss or smell plus taste loss. Less severe COVID-19 disease is related to a greater prevalence of anosmia. A quick recovery of the smell loss may be expected in most COVID-19 cases. CONCLUSION: Anosmia is more prevalent in COVID-19 patients than in patients suffering from other respiratory infections or controls.","Eur Arch Otorhinolaryngol","Printza, Athanasia","Constantinidis, Jannis","32447496"],"abstract":["PURPOSE: The sudden onset of smell and taste loss has been reported as a symptom related to COVID-19. There is urgent need to provide insight to the pandemic and evaluate anosmia as a potential screening symptom that might contribute to the decision to test suspected cases or guide quarantine instructions. METHODS: Systematic review of the PubMed/Medline, Cochrane databases and preprints up to May 3, 2020. Combined search terms included: \"COVID-19\", \"SARS-CoV-2\", \"coronavirus\", \"nose\", \"anosmia\", \"hyposmia\", \"olfactory loss\", \"smell loss\", \"taste loss\", and \"hypogeusia\". RESULTS: Our search identified 18 reviewed articles and 6 manuscript preprints, including a large epidemiological study, four observational case series, five case-controlled studies, five cross-sectional studies, five case series of anosmic patients and four electronic surveys. Great methodological differences were noted. A significant prevalence of anosmia is reported in COVID-19 patients. Controlled studies indicate that anosmia is more common in COVID-19 patients than in patients suffering from other viral infections or controls. Most of the studies reported either smell loss or smell plus taste loss. Less severe COVID-19 disease is related to a greater prevalence of anosmia. A quick recovery of the smell loss may be expected in most COVID-19 cases. CONCLUSION: Anosmia is more prevalent in COVID-19 patients than in patients suffering from other respiratory infections or controls."],"journal":"Eur Arch Otorhinolaryngol","authors":["Printza, Athanasia","Constantinidis, Jannis"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447496","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00405-020-06069-6","keywords":["anosmia","covid-19","loss of smell","olfactory dysfunction","sars-cov-2","taste"],"topics":["Diagnosis"],"weight":1,"_version_":1667698385875894272,"score":271.8292},{"pmid":32269598,"pmcid":"PMC7134577","title":"Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?","text":["Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?","There have been several reports noting anosmia and ageusia as possible symptoms of COVID-19. This is of particular interest in oncology since patients receiving some cancer treatments such as chemotherapy or immune therapy often experience similar symptoms as side-effects. The purpose of this report was to summarise the evidence on the existence of anosmia and ageusia an emerging COVID-19 symptoms in order to better inform both oncology patients and clinicians. Currently, there is no published evidence or case reports noting anosmia or ageusia as symptoms of COVID-19. Nevertheless, experts in rhinology have suggested that the onset of such symptoms could either act as a trigger for testing for the disease where possible, or could be a new criterion to self-isolate. Whilst more data is currently needed to strengthen our knowledge of the symptoms of COVID-19, oncology patients who are concerned about anosmia or ageusia in the context of their systemic anti-cancer therapy should contact their acute oncology support line for advice.","Ecancermedicalscience","Russell, Beth","Moss, Charlotte","Rigg, Anne","Hopkins, Claire","Papa, Sophie","Van Hemelrijck, Mieke","32269598"],"abstract":["There have been several reports noting anosmia and ageusia as possible symptoms of COVID-19. This is of particular interest in oncology since patients receiving some cancer treatments such as chemotherapy or immune therapy often experience similar symptoms as side-effects. The purpose of this report was to summarise the evidence on the existence of anosmia and ageusia an emerging COVID-19 symptoms in order to better inform both oncology patients and clinicians. Currently, there is no published evidence or case reports noting anosmia or ageusia as symptoms of COVID-19. Nevertheless, experts in rhinology have suggested that the onset of such symptoms could either act as a trigger for testing for the disease where possible, or could be a new criterion to self-isolate. Whilst more data is currently needed to strengthen our knowledge of the symptoms of COVID-19, oncology patients who are concerned about anosmia or ageusia in the context of their systemic anti-cancer therapy should contact their acute oncology support line for advice."],"journal":"Ecancermedicalscience","authors":["Russell, Beth","Moss, Charlotte","Rigg, Anne","Hopkins, Claire","Papa, Sophie","Van Hemelrijck, Mieke"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32269598","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3332/ecancer.2020.ed98","keywords":["covid-19","ageusia","anosmia","smell","taste"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491850850304,"score":270.5202}]}